Category Archives: Henan

Hunan Rolls Out 2026 TCM Pricing Governance Results – 10x Anchor‑Price Deadline, Risk Flags, and Listing Suspensions

Policy Snapshot

Item	Detail
Agency	Hunan Provincial Healthcare Security Bureau (China)
Document	Notice on Implementing the 2026 Price Governance Results for TCM Decoction Pieces and Formula Granules (Xiang Yi Bao Zhao Cai Han [2026] No. 114)
Legal Basis	Notice on Launching Price Governance of Listed Prices for TCM Decoction Pieces and Formula Granules (Xiang Yi Bao Zhao Cai Han [2026] No. 103)
Scope	TCM decoction pieces and formula granules listed on Hunan’s provincial procurement platform
Key Deadline	17:00, 24 Sep 2026 – cut listed prices to within 10x the anchor price
Sanctions	Listing suspension (from 3 months) for missed price cuts, unestablished distribution relationships, or non‑conforming invoice information
Appeal Window	3 months from the price‑risk‑flagging date, via the appeal module of the procurement subsystem
Channel Reopening	Listing applications and filing‑to‑sunshine‑listing conversions accepted again from 1 Oct 2026
Affected Products	Not disclosed in the notice body; itemized in five annexed lists

Governance Measures in Detail

Price‑Risk Flagging: Products whose manufacturers lowered listed prices within the designated window have been cross‑checked against provincial transaction data and marked with price‑risk flags in the bidding‑and‑procurement subsystem of the Hunan Healthcare Insurance Information Platform. Enterprises may review their flags directly; companies that later cut prices into compliance will have flags adjusted periodically under the stated rules.
Anchor‑Price Correction (10x Rule): Listed prices more than 10x the anchor price (10x itself excluded) fall within the correction scope. Manufacturers must reprice by the 24 September deadline; products that miss it – absent a pending complaint or appeal – will be suspended from the platform, while products under active appeal will be disposed of per the appeal handling opinions.
Compliance‑Based Suspensions: Separate suspensions (effective from the notice’s publication date, running at least three months) apply to products whose enterprises failed to establish required distribution relationships or whose invoice information remained non‑conforming after self‑inspection. Enterprises that subsequently remediate may apply for listing restoration.
Due‑Process Safeguards: A three‑month appeal window via the subsystem’s appeal module preserves a formal challenge path for companies disputing their risk flags.
Application Resumption: From 1 October 2026, Hunan resumes accepting new listing applications for TCM decoction pieces and formula granules, as well as conversions from filing to sunshine listing – signaling a return to normal channel operations after the governance round.

Market Impact & Outlook

Compliance Crunch: Manufacturers of flagged SKUs face a roughly six‑day repricing window between the notice date and the 24 September deadline – a tight turnaround that will test internal pricing governance at TCM producers selling into Hunan.
TCM Price Discipline Trend: The anchor‑price mechanism extends the centralized‑procurement playbook from chemical drugs into the historically fragmented TCM decoction‑pieces and formula‑granules market, where wide price dispersion across provinces has drawn sustained regulatory scrutiny.
Supply Continuity Risk: Suspensions of three months or longer could create temporary gaps in affected SKUs at Hunan public medical institutions; hospitals and distributors are advised to review the five annexed lists covering price‑correction products, missing distribution relationships, and invoice non‑conformities.
Structural Signal: Pairing enforcement suspensions with a firm 1 October reopening suggests Hunan views this round as a market‑clearing exercise rather than a prolonged freeze, with ongoing periodic flag adjustments keeping price discipline continuous.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory deadlines, appeal outcomes, suspension durations, and the resumption of listing applications for TCM decoction pieces and formula granules in Hunan Province. Actual results may differ due to risks including appeal handling decisions, enterprise remediation progress, and subsequent policy adjustments by the Hunan Provincial Healthcare Security Bureau.-China Health Reform Pulse

Policy Source: http://ybj.hunan.gov.cn/ybj/first113541/firstF/f3113607/202609/t20260918_34067089.html

Henan Proposes Standardizing and Consolidating Medical Services Pricing Items Across Four Clinical Categories – Public Consultation Open Through 17 September, With Parallel Cancellation Lists

Policy Milestone

Item	Detail
Issuing Agency	Henan Provincial Healthcare Security Administration – Department of Medical Commodity Pricing and Tender Procurement
Announcement Date	11 Sep 2026
Policy Basis	NHSA and seven other departments’ Notice on Issuing the Pilot Program for Deepening Medical Service Price Reform (Yi Bao Fa [2021] No. 41); NHSA project‑establishment guidelines for medical service price items
Scope	Standardization and consolidation of price items across digestive system; vascular & lymphatic system; maxillofacial surgery; general treatment categories
Dual Structure	Eight attachments: 4 consolidation drafts + 4 cancellation drafts (one pairing per category)
Comment Deadline	Before 17 September 2026 – written submission or electronic scan, bearing organizational seal or personal signature
Contact	Tel: 0371‑69690434; Email: hnsybjjgzc@126.com

Standardization & Consolidation Framework

Two‑Track Restructuring: For each of the four categories, the Administration has prepared both a draft of standardized/consolidated price items (Attachments 1–4) and a draft list of price items proposed for cancellation (Attachments 5–8) – signaling a deliberate slimming of Henan’s fragmented local price‑item catalog.
Category Pairing: Vascular and lymphatic system services are handled together as a single consolidated category, alongside digestive system, maxillofacial surgery and general treatment items.
National Guidelines Alignment: The restructuring implements the NHSA’s project‑establishment guidelines (立项指南) for medical service price items – part of the nationwide campaign to unify locally defined, inconsistently named service items under standardized national categories.
Pricing Reform Pilot Lineage: The plan operationalizes the 2021 eight‑department price reform pilot framework, which shifted the policy focus from item‑by‑item price adjustment toward structural standardization of what hospitals may charge and bill.
Draft Content: Specific item names, mappings and price levels are set out in the eight attachments and were not disclosed in the public notice itself.

Public Consultation Requirements

Eligible Submitters: Any organization or individual.
Format: Comments must be submitted in writing or as electronic scans to the Administration’s Department of Medical Commodity Pricing and Tender Procurement.
Authentication: Submissions must bear the official seal of the organization or the personal signature of the submitter; feedback is due before 17 September 2026.

Market Impact & Outlook

Catalog Rationalization: Consolidation paired with explicit cancellation lists will compress Henan’s billable service menu, eliminating overlapping, outdated or fragmented charge items – a prerequisite for transparent, comparable pricing across hospitals.
Hospital Billing Impact: Providers will need to remap billing systems and internal charge masters to the new standardized items, with abolished items requiring migration to consolidated equivalents.
National Convergence Signal: As more provinces issue guideline‑based restructuring drafts, Henan’s move reinforces the trajectory toward nationally uniform medical service price items, reducing cross‑province variation in how identical procedures are named and priced.
Price‑Level Uncertainty: The notice covers item standardization and consolidation, not the setting of new price levels; any subsequent price adjustments would follow separate provincial processes – details not disclosed.
Tight Window: The roughly six‑day comment period suggests the Administration intends to finalize the restructured catalog on a compressed timeline.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the finalization and implementation of Henan Province’s standardized and consolidated medical services pricing items. Actual outcomes may differ due to risks including public feedback, revisions to draft consolidation and cancellation lists, national guideline updates, and provincial implementation timing. The drafts remain subject to revision and do not constitute final policy.-China Health Reform Pulse

Policy Source: http://ylbz.henan.gov.cn/2026/09-11/3418603.html

Henan Adjusts Medical Consumables Payment Standards for Cardiac Devices

Leave a reply

Zhengzhou, Aug 28, 2026 — Henan Provincial Medical Security Bureau opened public consultations on adjusting medical insurance payment standards for select medical consumables, including coronary intervention balloon catheters and cardiac pacemakers, following provincial alliance procurement executions, while moving leadless pacemakers out of the negotiated consumables catalog into general management.

Policy Snapshot

Attribute	Detail
Issuer	Henan Provincial Medical Security Bureau
Document	Notice on Soliciting Opinions on Adjusting Payment Standards for Some Medical Consumables Under Medical Insurance
Scope	Coronary intervention balloon catheters; cardiac pacemakers; related inter-provincial alliance procurement batches
Key change	Leadless implantable cardiac pacemaker removed from negotiated consumables catalog, reclassified as general consumable
Legal basis	Henan Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Medical Consumables Catalog (2025) (Yu Yi Bao Ban [2025] No. 85)
Affected notices	Yu Yi Bao Ban [2026] No. 35 (10 batches); Yu Yi Bao Ban [2026] No. 47 (2 batches)
Comment deadline	Sept 12, 2026, 17:00 CST
Contact	Wang Minghua, 0371-69698064, hnybjyyc@126.com

Key Adjustments

The bureau proposed payment standard revisions for medical consumables covered under two provincial alliance procurement execution notices—one spanning 10 batches of coronary intervention balloons and related items, the other covering two batches of cardiac pacemakers. The most significant structural change involves the reclassification of the leadless implantable cardiac pacemaker from the negotiated consumables directory to general consumable management, effectively removing it from the separate negotiation track and subjecting it to standard reimbursement protocols.

Market Impact Analysis

The payment standard adjustments reflect the downstream policy synchronization that follows large-scale inter-provincial volume-based procurement for high-value cardiac devices. For manufacturers, the recalibration of reimbursement benchmarks will directly affect net pricing after insurance settlement, potentially compressing margins for coronary balloons and traditional pacemakers that were already subject to steep procurement-driven price cuts.

The reclassification of leadless pacemakers from negotiated to general consumable status is particularly consequential. Leadless pacemakers—premium devices that command significantly higher prices than conventional transvenous systems—had previously been shielded under the negotiated catalog, which typically allows for separate price agreements and more favorable reimbursement rates. Moving them to general consumable management signals a potential reimbursement downgrade, forcing manufacturers to absorb lower insurance payment ceilings or risk reduced hospital adoption as out-of-pocket costs rise for patients.

For hospitals and distributors, the adjustment clarifies the post-procurement reimbursement landscape, reducing administrative ambiguity but potentially tightening payment flows for high-end cardiac implants. The 15-day comment window suggests regulators intend to finalize standards by late September, leaving limited time for industry stakeholders to shape payment benchmarks.

Forward-Looking Statement

Industry analysts expect Henan’s template to be replicated across additional provinces that participated in the same inter-provincial procurement alliances, triggering a wave of payment standard harmonization for cardiac consumables in the fourth quarter of 2026. The leadless pacemaker reclassification may foreshadow a broader regulatory push to rationalize reimbursement tiers for premium implantable devices, potentially extending to structural heart and neurostimulation products. Companies with significant exposure to Henan’s cardiac device market should prepare for compressed reimbursement margins and evaluate pricing strategies that balance procurement compliance with sustainable hospital economics. Final rules are anticipated by late September or early October 2026.-China Health Reform Pulse

Policy Source: http://ylbz.henan.gov.cn/2026/08-28/3408750.html